Chronic Lymphocytic Leukemia (CLL) Developments For Patients & Caregivers (Ft. Dr. Nicole Lamann

2 Views

07/08/23

Top CLL specialist Nicole Lamanna, MD, of Columbia University discusses - in human terms - some of the more recent developments in treating chronic lymphocytic leukemia or CLL. She talks about new combinations of BTK & BCL2 inhibitors, understanding undetectable minimal residual disease or uMRD, the newer drug pirtobrutinib, CAR T-cell therapy, and much more.

The interview has only been edited for clarity.

Join Our Community:
Website: http://ThePatientStory.com
YouTube: https://www.youtube.com/ThePatientStory
Instagram: https://www.instagram.com/thepatientstory
Facebook: https://www.facebook.com/thepatientstory/
Twitter: https://twitter.com/patient_story
LinkedIn: https://www.linkedin.com/company/thepatientstory/
______________________________
Contents of this video:

00:00 - intro
04:02 - New combinations of BTK + BCL2 inhibitors
06:15 - Minimal residual disease (MRD)
07:36 - Understanding the different CLL detection tests
16:!2 - Would drugs like pirtobrutinib be indefinite treatment?
17:42 - Progress of CAR T-Cell therapy in CLL
23:19 - CLL treatment side effects
26:12 - BTK inhibitor common side effects
30:23- Comparing side effects of drugs in same class (earlier vs. newer)
33:29 - Who should go onto CAR T-cell therapy?
36:37 - New research studying BTK inhibitors + CAR T

______________________________
#ThePatientStory #chroniclymphocyticleukemia #CLL #cancerexperts #CLLTreatments #cllsm #leukemia #clinicaltrials #clinicalresearch btkinhibitors #ibrutinib #acalabrutinib #zanubrutinib #pirtobrutinib #venetoclax #ASH2021

Note: This is not medical advice and never a substitute for your own medical team. Please consult medical professionals for treatment information.